Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I admire your persistence.
Good Luck Jess
(Ariafan)
Jess, all the best to you and your family with your well deserved gains in Ariad. Your faith never wavered through all the trials and tribulations. One of your characteristics that I admired most in you was your thirst for knowledge by you continually asking questions. I saw you asking questions on numerous boards across the iHub universe. Well done!
Just off the phone with a hedgie who also wanted a bit more.
3 law firms said same.They apparently tried to get Takeda to make some alternate option available. "Ain't gonna happen", but we move on!
We have a biotech scanner with 622 worldwide firms on same-same. Was 623 prior to this takeout! Some look very promising, some not so much. Takeda is solid, spending like crazy, so we move on from them as well. Like to use 14 technical s in DD and we pretty much eliminate low volume OTC firms. Our pricing models also use our algos to compute RTR on each. A RTR of 3 is about max after calculating based on our 497 years of collective experience.Beyond that loss ratio increases exponentially.
Lots of M&A activity ongoing as we communicate.
GL.
LMAO!
Why don't you contact Him and see where He would invest the proceeds. LOL. BTW: Lots of M& A action ongoing in biotech.
You know it is getting close when you check your account and ARIA is no longer listed by name.
ARIAD Announces Submission of Marketing Authorization Application for Brigatinib to the European Medicines Agency
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the submission of a Marketing Authorization Application (MAA) for its investigational oral anaplastic lymphoma kinase (ALK) inhibitor, brigatinib, to the European Medicines Agency (EMA). ARIAD is seeking marketing approval in the European Union of brigatinib in adult patients with anaplastic lymphoma kinase (ALK+) non-small cell lung cancer (NSCLC) who have been previously treated with crizotinib. The U.S. Food and Drug Administration (FDA) is currently reviewing a New Drug Application for brigatinib filed by ARIAD and has set an action date of April 29, 2017 under the Prescription Drug User Fee Act (PDUFA).
“ARIAD's submission of the brigatinib MAA to the EMA is one of many recent milestones highlighting our strong investment in internally discovered rare cancer therapies,” said Paris Panayiotopoulos, president and chief executive officer of ARIAD. “Since announcing our definitive agreement to combine with Takeda, we remain focused on our accountability to our patients by propelling brigatinib forward and by preparing for its anticipated U.S. launch.”
“The brigatinib clinical trials have provided patients with refractory ALK+ NSCLC, including those patients who have metastatic brain lesions, with a potential important treatment option,” said Maurice Perol, MD, Léon Bérard Cancer Center, Lyon, France. “Based on the clinical data we’ve seen to date, we are really excited by the prospect that appropriate patients in the EU may have access to brigatinib as a new targeted treatment.”
ARIAD’s MAA submission includes clinical data from its Phase 1/2 and pivotal Phase 2 ALTA trials of brigatinib. Results from the ALTA trial and central nervous system (CNS) activity in the ALTA and Phase 1/2 trials were reported at the International Association for the Study of Lung Cancer (IASLC) 17th World Conference on Lung Cancer (WCLC) in December 2016. In the ALTA trial, 222 patients received either 90 mg of brigatinib once per day (QD) continuously or 180 mg QD, preceded by a lead-in dose of 90 mg QD for seven days. Data from the ALTA trial demonstrated that of 110 patients on the 180-mg regimen QD with a seven-day lead-in at 90 mg QD with a median follow-up of 11.0 months, 55 percent achieved confirmed objective response as assessed by the investigator. In this arm, the median progression-free survival (PFS) was 15.6 months in this post-crizotinib setting, by both investigator and independent review committee (IRC) assessment. Additionally, in this arm, 67 percent (12/18) of patients with measurable brain metastases achieved a confirmed intracranial objective response. The most common treatment-emergent adverse events (TEAEs; ≥ 25% of all patients in this arm, regardless of relationship to treatment), were nausea (43%), fatigue (40%), diarrhea (39%), cough (36%), increased blood creatine phosphokinase (CPK) (33%), headache (30%), rash (28%), and vomiting (26%). The most common serious adverse reactions other than neoplasm progression reported in 2% or more of patients included pneumonia (5.0%), pneumonitis (5.0%) and epilepsy (2.3%). A subset of pulmonary adverse events (AEs) with early onset (median: Day 2; range: Day 1-9) occurred in 6.4 percent of all patients (grade ≥3 in 3% of patients); no such events with early onset occurred after dose escalation to 180 mg QD following the lead-in dose of 90 mg for seven days.
About Brigatinib
Brigatinib is an investigational, targeted cancer medicine discovered internally at ARIAD. It is in development for the treatment of patients with anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC). The global Phase 2 ALTA trial, in patients with locally advanced or metastatic ALK+ NSCLC who were previously treated with crizotinib, is the primary basis for brigatinib’s initial regulatory review. ARIAD has also initiated the Phase 3 ALTA 1L trial to assess the efficacy and safety of brigatinib in comparison to crizotinib in patients with locally advanced or metastatic ALK+ NSCLC who have not received prior treatment with an ALK inhibitor. More information on brigatinib clinical trials can be found here.
Brigatinib received Breakthrough Therapy designation from the FDA for the treatment of patients with ALK+ NSCLC whose tumors are resistant to crizotinib, and was granted Orphan Drug designation by the FDA for the treatment of ALK+, ROS1+ and EGFR+ NSCLC.
About ALK+ NSCLC
Non-small cell lung cancer (NSCLC) is the most common form of lung cancer, accounting for approximately 80 to 85 percent of the estimated 222,500 new cases of lung cancer diagnosed each year in the United States, according to the American Cancer Society. Anaplastic lymphoma kinase (ALK) was first identified as a chromosomal rearrangement in anaplastic large-cell lymphoma (ALCL). Genetic studies indicate that chromosomal rearrangements in ALK are key drivers in a subset of NSCLC patients as well. Approximately five percent of patients with NSCLC have a rearrangement in the ALK gene, according to the American Cancer Society.
About ARIAD
ARIAD Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is focused on discovering, developing and commercializing precision therapies for patients with rare cancers. ARIAD is working on new medicines to advance the treatment of rare forms of chronic and acute leukemia, lung cancer and other rare cancers. On January 9, 2017, it was announced that ARIAD has entered into a definitive agreement to be acquired by Takeda. The transaction is expected to close by the end of February 2017, subject to customary closing conditions. For additional information, visit http://www.ariad.com or follow ARIAD on Twitter (@ARIADPharm).
Forward-Looking Statements
This press release contains forward-looking statements. Any statements contained herein which do not describe historical facts, including, but not limited to, statements regarding regulatory filings for brigatinib and the therapeutic potential of brigatinib, the anticipated timing for approval of brigatinib in the United States, the announced merger between ARIAD and Takeda, ARIAD’s continued efforts to develop brigatinib, ARIAD’s plans for the potential U.S. launch of brigatinib, and the potential of brigatinib as a new treatment option, are forward-looking statements which are based on management's expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcome of events, timing and performance to differ materially from those expressed or implied by such statements. These factors, risks and uncertainties include, among others: risks related to the satisfaction of the conditions to closing the Takeda acquisition (including the failure to obtain necessary regulatory approvals) in the anticipated timeframe or at all, including uncertainties as to how many of ARIAD’s stockholders will tender their shares in the tender offer and the possibility that the acquisition does not close; early-stage clinical data may not be replicated in later-stage clinical studies; the costs associated with our research, development, manufacturing and other activities; the adequacy of our capital resources and the availability of additional funding; our ongoing and additional clinical trials of brigatinib may not be successful or initiated, enrolled or conducted in a timely manner; our ability to meet anticipated regulatory filing and approval dates for brigatinib; regulatory developments and safety issues, including difficulties or delays in obtaining regulatory and pricing and reimbursement approvals for brigatinib; competitive risks; manufacturing issues; the uncertainties inherent in research and development, including the ability to sustain and increase the rate of growth in revenues for ARIAD’s products despite increasing competitive, reimbursement and economic challenges; whether and when any drug applications may be filed in any jurisdictions for any indications or any additional indications for ARIAD’s products or for ARIAD’s pipeline assets; whether and when the FDA, EMA or any other applicable regulatory authorities may approve any such applications, which will depend on its assessment of the benefit-risk profile suggested by the totality of the efficacy and safety information submitted; decisions by the FDA, EMA or other regulatory authorities regarding labeling and other matters that could affect the availability or commercial potential of ARIAD’s products and ARIAD’s pipeline assets; and competitive developments; and those additional factors detailed in our public filings with the U.S. Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and subsequent quarterly and current reports on Form 10-Q and Form 8-K. Except as otherwise noted, these forward-looking statements speak only as of the date of this press release and we undertake no obligation to update or revise any of these statements to reflect events or circumstances occurring after this press release. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. All forward-looking statements in this press release are qualified in their entirety by this cautionary statement.
http://cts.businesswire.com/ct/CT?id=bwnews&sty=20170206005112r1&sid=acqr7&distro=nx&lang=en
View source version on businesswire.com: http://www.businesswire.com/news/home/20170206005112/en/
ARIAD Pharmaceuticals, Inc.
For Investors
Manmeet Soni, 617-503-7298
manmeet.soni@ariad.com
or
For Media
Liza Heapes, 617-621-2315
Liza.heapes@ariad.com
Source: ARIAD Pharmaceuticals, Inc.
© Copyright Business Wire 2017
Yeah, it's not going to happen but waiting till tender offer of cash is not in vain. It can gain you the top trim of a luxury car. A lot of people sold at 23.75 four weeks ago. I just have to wait now for 3 days to maximize my profit. Whatever our differences are in the past, I hope you made money in this stock. It was a long journey full of drama and gut aches but it's worth it in the end. New chapter BR....good luck to your next stop.
I know Pup and Jesspro wanted something different, but that is not going to happen.....
The name of this show is "24". Where's Keifer Sutherland when you really need him?
I know, and once again simply trying to get some to do more DD in the event a "option" was to be made available. We've seen situations where such an option is offered at a later date to encourage investors to look more closely at a parent company But, considering the way Takeda is burning thru cash it becomes ??????.
Further, after several discussions with a few law firms we have concluded the SEC filings would not be altered, tweaked at a later date. This is legal if same is filed for by a foreign company in their Home Office.
Bottom line, 24.00 is the "bottom line.
GL.
The Pup, there never was a "might" be offered. If that was an option, it would HAVE TO BE in the SEC filing. It WAS NOT..
Amazing how the human mind can wander to wherever it may want to go, for whatever reason. LOL. No one is looking for an "alternative to an all cash offer"! Simply stated we have often experienced offers to rade shares in these M&A/takeovers. Obviously NOt the case here, but so why misinterpret a Post saying is sometimes happens???
So we take the cash and go elsewhere where maybe ownership in another company could be offered, if at all. LMAO!
Amazing how the human mind can wander to wherever it may want to go, for whatever reason. LOL. No one is looking for an "alternative to an all cash offer"! Simply stated we have often experienced offers to rade shares in these M&A/takeovers. Obviously NOt the case here, but so why misinterpret a Post saying is sometimes happens???
So we take the cash and go elsewhere where maybe ownership in another company could be offered, if at all. LMAO!
Never said there was this option in this particular matter "bio". Simply stated it MIGHT be offered as it has with so many companies. Could be offered at any time, but agree, to date see nothing of the sort. The 24.00 is a descent PPS anyway, so onward and upward looking for a new "home" with the $$$$$.
GL.
At some point they will LOCK the board. History will still be there, but wont allow any further post.
Another Denner holding Apri watch closely
Right. That post might have been the first time I have ever seen anyone look for alternatives to an all-cash offer!
The pup, sorry, but this is not an option. There is absolutely no option to take a partial share of Takeda stock instead of cash. Zero. You can take the $24 per share in cash and purchase Takeda stock, on some exchange I suppose, but I sure wouldn't as they have been on a spending spree.. There is nothing in the SEC filings that provide for this option..
Agreed, however, one may be offered a option in shares of Takeda, if offered. Some of same may offer a proportionate number of shares of parent company if offered, so that is a possibility. So if one has say 1,000 shares of Ariad @ 24.00 and Takeda is trading at 48.00 one would POSSIBLY be offered .5 of a share of Takeda for each share of ARIAD, or 500 shares of Takeda. As of this date we do not see this option??
The board will stick around and still be called ARIA. For example - RLYP was bought out a while ago and the RLYP board is still there.
Anyone know what iHub's protocol is for message boards relating to companies that are acquired? Will the ARIA board disappear and if so when?
They just need 51% of the shares tendered by 2/15 to complete the deal...I am sure they have that tender amount already...if you don't tender, you will just have to wait a little while longer to get your cash!!
Sorry soniccity, you need a new broker. If you do nothing, your shares will automatically be converted to $24 per share, which will be a wonderful thing. There is no other outcome as Ariad shares will no longer trade..
Hello all, I have a question. I am new to these cash deals like Takeda has done, I was in my local Scottrade office and asked about the buy out and he looked at the deal and informed me that a non-tender offer was not a buyout and I could actually do nothing and keep the stock if I felt that was a better option than taking the deal. is this true? Is Aria stock still going to exist after Feb 15th? Would the shorts covering after that date push it over 24$?
Thanks.
Hey all you successful Ariad investors flush with money. Galena is back in play, up over 100% pre market on positive news for their new trials on Neuvax. Also seems last years independent study saying it was futile was not accurate.... just thought I'd share. (I'm long Gale and also won on Ariad, patience pays off....)
What is Denner's next play?
Exactly!
Possible that a slightly higher offer may come in per the Wall St. gurus we communicate with. Some lawyers want more as well. Anyway, 24.00 withstanding. Have query's out to some lawyers now, so we shall see. Don't expect much but if we do it has to be fairly soon as deal set for vote prior to end of Month.
Any thought s on Infinity pharma. I bought in today and it plunged 10% after I bought. Poor timing on my part.
Vid, 2 damoon, Jesspro Mr palmer???
I started posting on the INFI IHUB board if anyone wants to join.
MDCO another Denner deal is up $5.25 after hours. Don't remember who posted here but I bought right after the announcement on ARIA.
NICE.....
biotech reseacher; what do you make of !
http://ih.advfn.com/p.php?pid=nmona&article=73728734
Seems to of moved ah. txs glty.
I've been saying that for months. They locked in their profits. Covered their own short position with shares they owned and postponed the profit until 2017.
It's not hard to figure out!
I'm guessing, but I suspect those shorts may be in place as some sort of hedge.
Some had speculated that when the convertible issue was done, several purchased that security while shorting the common. As I said back then, I'm not sure how the mechanics of this works out, but that doesn't mean it doesn't.
rum
Sold all my shares last week and wanted to thank all the great posters on this board.....as well as Dr. Denner and his senior team of executives and all the other terrific folks at Ariad.
I'm very happy with the $24/sh offer and feel this was a very fair price at this moment in time. No one knows what the future holds so I'll take my nice profits and look to move up my retirement by about six years!
Thanks all and best wishes to everyone!
I don't expect a higher offer, so I sold my ARIAS position. Id did, however, buy some Feb 24 calls for a nickel each ($5 per contract) just in case a higher offer were to emerge before the buyout is completed.
True but if someone else comes in with a better offer than the shorts are in deeper water.
True but if someone else comes in with a better offer than the shorts are in deeper water.
From now until the cash conversion day there is still small possibility for Takeda to back out from the deal. For example, what if Takeda reviewed the recent SEC filing and found out Araid management wasn't honest and played hardball to boost buyout price. Or FDA requests more data for Briga and extend the approval deadline beyond 04/29/17, etc.
By waiting until the cash-out day, it will cost the shorts only $.20 -> $.30/share, but if Tekada backs out from the deal, shorts will win the jackpot. There is no need for them to cover now.
tste9, you are going to be fine. The deal will close before the end of February. In the highly unlikely event that it does unravel, the share price would drop to $11-$12 range and I would re-enter there..
biotech reseacher; Sorry, BUT dumb canuck question "what!" 'you're back in if taladaga backs out'. I don't get. Please respond. glty
PS I know you sold 23.80.
I don't know all about this short interest stuff. But if you could explain, why are shorts still in this stock. It is $ 24.00 in a few weeks.
And... Why is their still large Vol. trading when this is a done deal. txs confused canuck.
Just as most of us didn't expect the BO could happen so quickly at this very generous $24/share cash offer (while Briga still hasn't been approved by FDA), the unexpected could happen again and lead to Takeda backing out from the deal, then SP could drop below the privious level under $13/share
Good lucks to those are still holding shares for pennies.
Why would you go back in? Backing out of the deal would mean a huge red flag and I don't think anybody else would jump in with another offer anytime soon.JMO
If Takeda backs out, I'm back in. Share price will telegraph it..
Latest short interest:
1/13/2017 , 23,605,983 , 32,042,457 , 1.000000
12/30/2016 , 31,830,948 , 2,791,096 , 11.404462
12/15/2016 , 32,405,235 , 4,537,777 , 7.141214
http://www.nasdaq.com/symbol/aria/short-interest
Shorts still covered all the shares... Wonder what they're waiting for? Are they hoping for Takeda backing out from the deal? Anyone know how much Takeda will have to pay Ariad for backout? Thx!
Ptr. 40 next week
I've been watching MDCO for a awhile & Agree with dew about the notable purchases
Denner is in MDCO. March timeframe for a pop on a drug. Chart looks good.
Post from Dew
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=122674290
the tender is in process
Jesspro,
I know it's hard to understand but in all reality 788 is probably worth $0 if using a current valuation.
That does not mean that 788 is worthless by any means. What it means is that someone is going to have to spend enormous sums of money and take huge risks to find out really if it is a viable product.
Those costs are why a partner would come to Ariad and say: Hey, I'll give you $20 mil upfront and a portion of the future profit if you let me put 788 through trials and FDA approvals. As anyone knows, many if not the majority of these agreements go nowhere.
And again, the $20 mil is a rounding error in the $5 Billion dollar deal.
Jbog, if they didn't put any value to 788, could they have been allowed to sell the patent of 788 to another party to recover the expenses they spent on that drug after all they considered it for an unmet medical need? Or did they see something in that drug that it's not going to take off anyway?
Followers
|
284
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
80490
|
Created
|
10/26/03
|
Type
|
Free
|
Moderators |
http://www.ariad.com/
http://finance.yahoo.com/q/ks?s=ARIA
http://phx.corporate-ir.net/phoenix.zhtml?c=118422&p=irol-news&nyo=0
The name ARIAD originates from the Greek myth of Ariadne, a daughter of Minos II, king of Crete. According to the myth, Ariadne fell in love with Theseus and gave him a spool of thread that enabled him to trace his path safely in and out of the labyrinth in which the Minotaur lived.
After slaying the Minotaur, Theseus used the spool of thread to successfully return home. From ARIAD's perspective, the labyrinth symbolizes the complex system of molecular pathways within the cell, and the spool of thread represents the signaling pathways that are leading our scientists to the discovery of breakthrough cancer therapies.
http://data.cnbc.com/quotes/ARIA/tab/8
http://data.cnbc.com/quotes/ARIA/tab/8
ARIA charts here.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=75384935
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |